About DVS Sciences
DVS Sciences is a company based in San Francisco (United States) founded in 2004 was acquired by Fluidigm in January 2014. DVS Sciences has raised $18.73 million across 2 funding rounds from investors including Pfizer, Fluidigm and Ontario Institute for Cancer Research. DVS Sciences operates in a competitive market with competitors including Cepheid, Beckman Coulter, Blackrock Neurotech, Bruker and Esco Lifesciences, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of DVS Sciences
DVS Sciences has successfully raised a total of $18.73M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $14.6 million completed in July 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in DVS Sciences
DVS Sciences has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Fluidigm and Ontario Institute for Cancer Research.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
Venture capital investments are managed in technology and healthcare sectors by this firm.
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital firm focused on the healthcare sector
|
Locked | Locked | Locked |
Investor details for DVS Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DVS Sciences
Investment portfolio details for DVS Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DVS Sciences
Detailed financials for DVS Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dvs Sciences Comparisons
Peer comparison for DVS Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DVS Sciences
DVS Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Beckman Coulter, Blackrock Neurotech, Bruker and Esco Lifesciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of molecular diagnostic testing solutions
|
|
| Locked | Locked | Locked |
Provider of products for biomedical testing for R&D, diagnostic and commercial applications
|
|
| Locked | Locked | Locked |
Medical devices for neurological therapies are developed.
|
|
| Locked | Locked | Locked |
Diversified research instrument systems are manufactured and supplied.
|
|
| Locked | Locked | Locked |
Manufacturer of biopharma equipment & IVF medical devices, and service provider for life science tools
|
|
| Locked | Locked | Locked |
Diversified instruments are developed for scientific and laboratory management.
|
Detailed competitors of DVS Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dvs Sciences
Complete news archive for DVS Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DVS Sciences
DVS Sciences was founded in 2004 and raised its 1st funding round 7 years after it was founded.
DVS Sciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
DVS Sciences is a funded company, having raised a total of $18.73M across 2 funding rounds to date.
DVS Sciences was founded in 2004 in San Francisco, United States. Bioanalytical solutions focused on life sciences are manufactured and distributed worldwide. Operations center on a patented multi-parameter system that includes the CyTOF mass cytometer for quantitative single-cell analysis and MAXPAR reagents featuring stable-isotope-tagged antibodies. Global reach supports research and analytical applications in biotechnology.
DVS Sciences's top competitors include Cepheid, Blackrock Neurotech and Agilent.
DVS Sciences has 6 investors. Key investors include Pfizer, Fluidigm, Ontario Institute for Cancer Research, 5AM Ventures, and Mohr Davidow Ventures.